Condition: Recurrent Glioblastoma · Glioblastoma · Glioma, Malignant · Sponsor: David Reardon, MD
The goal of this study is to evaluate the safety of the experimental drug, CUE-102, and establish the recommended dose of CUE-102 for participants with Recurrent Glioblastoma (GBM). The name of the study drug involved in this study is: -CUE-102 (a type of fusion protein)
This description comes directly from the study's public registry record.
David Reardon, MD · 617-632-4750 · david_reardon@dfci.harvard.edu
Always discuss trial participation with your own doctor first.
| Brigham and Women's Hospital | Boston, Massachusetts, United States | Not Yet Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06917885